Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Samsung Biologics wants a piece of the GLP-1 boom. The Korean manufacturing giant has offered to buy PolyPeptide, a Swiss peptide manufacturer, in an all-cash deal worth about $1.8 billion.
Under the terms, PolyPeptide shareholders will receive CHF 44.31 per share. That works out to roughly $55.17 at current exchange rates. Notably, PolyPeptide’s board already reviewed the offer and unanimously recommended it to shareholders.
Both companies hope to close the deal by the end of 2026. That’s an ambitious timeline for a cross-border acquisition this size. Still, neither side has flagged major concerns so far.
So why does a biologics manufacturer suddenly want a peptide company? The answer comes down to one word: GLP-1.
Samsung has spent years building out its manufacturing capabilities. Until now, though, it mostly stuck to producing biologics for pharmaceutical partners. This deal changes that path. PolyPeptide brings real expertise in peptide synthesis, which happens to be exactly what GLP-1 drugs require.
That expertise matters more than it might seem. Peptide manufacturing is notoriously difficult, and it differs quite a bit from standard biologics production. As a result, companies that can do it well and do it at scale are suddenly in high demand.
It helps to understand why GLP-1 drugs became such a hot commodity in the first place. These medications mimic a hormone the body naturally produces, called glucagon-like peptide-1. GLP-1 regulates blood sugar, slows digestion, and helps people feel full longer. Together, these effects make the drugs remarkably effective for both type 2 diabetes and weight loss.
Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro, have become household names in recent years. All three remain prescription-only medications. Meanwhile, the FDA continues to monitor their safety and labeling closely for both type 2 diabetes and weight loss.
However, demand has outpaced supply for a long time now. Shortages have become a recurring headache for patients and pharmacies alike, and the cost of these treatments remains a concern for many without insurance coverage. That ongoing supply crunch is really what’s driving deals like this one.
Samsung isn’t alone in throwing money at the problem, either. Eli Lilly committed $3.5 billion to build a GLP-1 manufacturing facility in Pennsylvania. Novo Nordisk, for its part, has been expanding operations in North Carolina and Ireland.
In short, everyone wants a bigger slice of the peptide manufacturing pie. And companies are willing to spend big to get it.
Still, buying a company won’t automatically solve the supply problem. Scaling up manufacturing capacity takes time, regardless of who owns the facility. Plants need regulatory approval. Production lines need validation. None of that happens quickly, even after a deal officially closes.
Regulatory review adds another layer of complexity. This deal involves a Swiss company with operations across several countries. Therefore, it will likely need antitrust clearance and foreign investment checks in multiple jurisdictions. So far, though, neither company has raised concerns about that process.
For now, shareholders must approve the deal through the tender offer process. If that goes smoothly, Samsung expects to close the acquisition before year’s end.
This deal reflects something bigger than a single transaction, though. It fits into a broader wave of consolidation in contract manufacturing, as companies race to build capacity around today’s most in-demand therapies. As more health systems turn to GLP-1 treatments for obesity and diabetes, manufacturers that can produce these drugs reliably and at scale stand to gain the most.
That said, patients shouldn’t expect this deal to ease shortages anytime soon. Meaningful capacity changes take years, not months. Even so, the acquisition signals clearly where pharmaceutical manufacturing is headed. And Samsung, evidently, doesn’t want to be left behind.
